Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
December 11, 2017 10:00 ET
|
eFFECTOR Therapeutics
Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR...
eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
November 10, 2017 10:00 ET
|
EFFECTOR Therapeutics
SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster...
eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
October 04, 2017 10:00 ET
|
EFFECTOR Therapeutics
SAN DIEGO, Oct. 04, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has...
Pet Cancer Therapeutics Market worth over $300 million by 2024: Global Market Insights, Inc.
August 09, 2017 06:30 ET
|
Global Market Insights, Inc
Ocean View, Delaware, Aug. 09, 2017 (GLOBE NEWSWIRE) -- The Industry Analysis report “Pet Cancer Therapeutics Market By Medicine Type (Chemotherapy Drugs and Vaccines), By Species (Dogs and Cats),...
Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)
May 15, 2017 06:22 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China
November 29, 2016 07:16 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
From Nurse to Patient
February 06, 2014 17:44 ET
|
Genentech
MISSION, KS--(Marketwired - Feb 6, 2014) - (Family Features) Despite her career as a scrub nurse for general cancer surgeries, a personal diagnosis of cancer still came as a surprise.
"It...
MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent in Korea
January 31, 2014 08:35 ET
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Jan 31, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic...
MMRGlobal Adds Japan & South Korea to China in Filing of Cancer Fighting Patent Under Expedited Patent Allowance Program
August 26, 2013 08:35 ET
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Aug 26, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic...
Lack of Information Biggest Barrier for Lymphoma Patients
December 21, 2012 15:54 ET
|
Lymphoma Coalition
Mississauga, Ontario, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Lack of basic, but crucial, information acts as a barrier to the
proper diagnosis and treatment of lymphoma patients worldwide. This
contributes...